Establishment of a clinically applicable human tyrosine hdroxylase DNA vaccine for anti-neuroblastoma immunotherapie

DNA vaccination against cancer antigens often induces weak anti-tumor immune responses in humans. In order to enhance the effect, xenogeneic immunization is a promising approach, in particular for neuroblastoma (NB), the most common extracranial solid tumor in childhood. NB cells highly express the enzyme tyrosine hydroxylase (TH). A human TH (hTH) DNA vaccine has already been investigated in a syngeneic NB mouse model leading to complete remission of established tumor and of metastasis. With regard to clinical application different aspects of the xenogeneic TH DNA vaccination approach have to de readjusted. For…